NEWS: GI Toxicity Study Using EVOM Auto Released
A new study by Altis Biosystems (Durham, NC) using the EVOM™ Auto is undergoing a peer review prior to publication. It addresses the challenge of predicting gastrointestinal toxicities (GITs) in drug development, which are common adverse events in clinical trials. Traditional animal models fail to accurately replicate human GI physiology, leading to late detection of GITs. Researchers Colleen Pike and James Levi (with their team) developed a high-throughput assay, a 2D human intestinal stem cell-derived model, which assesses cell proliferation, cell abundance, and barrier function to predict clinical diarrhea risk. The assay demonstrated high accuracy in predicting diarrhea potential for 30 drugs. TEER (transepithelial electrical resistance) measurements were used to asses the barrier function of the cellular layers. They were able to predict with high accuracy which drugs were likely to cause GIT. This in vitro model could improve early safety evaluations, reducing adverse events in clinical trials and leading to safer treatments.
WPI's EVOM™ Auto Automated TEER Measurement System was used to assess the barrier integrity of the cell monolayer in the 2D model. TEER measurements were taken daily to evaluate the formation and maintenance of the barrier function, which is a key indicator of the model's physiological relevance and response to drug exposure.
